| Mckenna Osterhout, | |
|
1492 S Silicon Way, St George, UT 84770-7155 | |
| (435) 275-8911 | |
| Not Available |
| Full Name | Mckenna Osterhout |
|---|---|
| Gender | Female |
| Speciality | Community Health Worker |
| Location | 1492 S Silicon Way, St George, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1568812576 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101Y00000X | Counselor | (* (Not Available)) | Secondary |
| 172V00000X | Community Health Worker | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mckenna Osterhout, 1492 S Silicon Way, St George, UT 84770-7155 Ph: (435) 275-8911 | Mckenna Osterhout, 1492 S Silicon Way, St George, UT 84770-7155 Ph: (435) 275-8911 |
News Archive
Ligand Pharmaceuticals Incorporated has amended its license agreement with Exelixis, Inc. as a result of which Ligand is now entitled to receive royalties on net sales of future products from a mineralocorticoid receptor program and a one-time $75,000 payment for providing access to certain patent rights.
Scientists at the Helmholtz Zentrum München and the Ludwig Maximilians University of Munich have developed a new method of predicting disease progression in gliobastoma patients who have undergone standard treatment.
Home Diagnostics, Inc., a leading developer, manufacturer, and marketer of blood glucose monitoring systems, today announced the results of a TRUE2go™ clinical performance study published in the October 2009 issue of the journal Diabetes Technology & Therapeutics. The study, "Clinical Performance of the TRUE2go Blood Glucose System – A Novel Integrated System for Meter and Strips," demonstrated the accuracy and precision of the TRUE2go system and found that it was both easy and convenient to use by patients.
Scientists at Emory University School of Medicine have identified a new type of anti-inflammatory compound that may be useful in treating a wide range of conditions, including neurodegenerative and autoimmune diseases. These compounds inhibit the enzyme Nox2, part of a family of enzymes responsible for producing reactive oxygen species (ROS).
Dr. Stanley Fineman, president of the American College of Allergy, Asthma and Immunology, (ACAAI) is available to comment on the School Access to Emergency Epinephrine Act, a federal bill introduced today that will help make epinephrine available in schools for the immediate treatment of anaphylactic reactions to food or other allergens.
› Verified 7 days ago